← Back
Bridgebio Pharma
BBIO · listed on Nasdaq · worth $13.24 billion
$68.15
−0.13% on Oct 29
No insider bought Bridgebio Pharma stock in the last year. They sold it 115 times, $81.39 million in all. One member of Congress reported trading Bridgebio Pharma in the last year.
Red dot = an insider soldA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
167.2M shares
86% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, nine insiders sold Bridgebio Pharma stock and none bought. 13 of the 115 sales are marked on the filing as planned in advance; most by company executives. The biggest seller was Neil Kumar, Chief Executive Officer.
Planned sales
Form 144 notices filed for Bridgebio Pharma in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
CEO Neil Kumar filed to sell 30,000 shares on 19 Aug; sold 54,980 by 17 Sep, more than the notice named10b5-1 plan adopted 13 May 2026 · Notice on SEC.gov
CEO Neil Kumar filed to sell 34,980 shares on 18 Aug; no sale reported yet10b5-1 plan adopted 13 May 2026 · Notice on SEC.gov
Director Randal W. Scott filed to sell 21,501 shares on 17 Aug; no sale reported yet10b5-1 plan adopted 27 Jun 2025 · Notice on SEC.gov
Big investors
People and funds that reported owning 5% or more of Bridgebio Pharma, newest first.
Filed by someone who owns 5% or more and may try to influence how the company is run. · updateKKR Genetic Disorder L.P.4.2%Aug 17
Filed by someone who owns 5% or more and does not plan to influence the company. · updateFarallon Capital Management5.5%Aug 3
Filed by someone who owns 5% or more and may try to influence how the company is run. · updateViking Global Investors LP5.0%Jul 10
US Congress
Members of Congress who reported trading Bridgebio Pharma in the last year. They have up to 45 days to report, so the newest trades show up late.
MemberTradeAmountWhose accountTradedReported
All reports
Every insider trade and SEC report we hold for Bridgebio Pharma.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Sep 21SoldNeil KumarSep 21 · Traded Sep 17 · Chief Executive Officer · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.via a trust or family1,279 @ $69.57$89K
Sep 21SoldNeil KumarSep 21 · Traded Sep 17 · Chief Executive Officer · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.via a trust or family8,721 @ $69.01$601.9K
Aug 20SoldNeil KumarAug 20 · Traded Aug 19 · Chief Executive Officer · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.via a trust or family100 @ $85.65$8.6K
Aug 20SoldNeil KumarAug 20 · Traded Aug 19 · Chief Executive Officer · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.via a trust or family1,800 @ $84.69$152.4K
Aug 20SoldNeil KumarAug 20 · Traded Aug 19 · Chief Executive Officer · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.via a trust or family8,100 @ $83.86$679.3K
164 more with Pro →Analysts, earnings and news
Analysts' price target
$102.47 average
22 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
1 of 4 quarters above
Q1 '26−$0.84 a share−$0.22
Q4 '25−$0.94 a share−$0.32
Q3 '25−$0.72 a share+$0.06
Q2 '25−$0.95 a share−$0.35